Description

Cagrilintide + Semaglutide 5mg × 10 vials

A dual metabolic research blend combining cagrilintide, a long-acting amylin analogue, with semaglutide, a GLP-1 receptor agonist. This combination is studied for weight management research, appetite regulation, satiety signaling, glucose-related pathways, and broader metabolic support protocols.

Product Overview

Compound: Cagrilintide + Semaglutide
Strength: 5 mg per vial
Injection type: Subcutaneous
Frequency: Research protocol dependent

Reconstitution

Amount in vial: 5 mg
BAC water: 2 mL
Amount per unit: 25 mcg per unit

Research Dose

Protocol dependent.

Notes

Cagrilintide + Semaglutide is a combination of two metabolic research compounds: cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist.

This combination is being studied in clinical research settings under the name CagriSema for obesity, weight management, and type 2 diabetes-related protocols. It should not be positioned as a general wellness product or assumed to have a standard consumer dosing protocol.

Use only within appropriate research or professional guidance frameworks.

Disclaimer

This product is intended for research and informational purposes only.